Cargando…

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

OBJECTIVE: Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Yuta, Morita, Takayoshi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197806/
https://www.ncbi.nlm.nih.gov/pubmed/32373775
http://dx.doi.org/10.1093/rap/rkaa008
_version_ 1783528886772957184
author Yamaguchi, Yuta
Morita, Takayoshi
Kumanogoh, Atsushi
author_facet Yamaguchi, Yuta
Morita, Takayoshi
Kumanogoh, Atsushi
author_sort Yamaguchi, Yuta
collection PubMed
description OBJECTIVE: Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients with GIO. METHODS: A comprehensive systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PubMed, Web of Science and Google Scholar were used to search for original studies reported about BMD in patients with GIO treated with denosumab. In meta-analysis of BMD, the mean difference in the rate of change from baseline and the 95% CI were calculated using the random effects model. The mean differences in patients treated with denosumab were compared with those in patients treated with bisphosphonates. RESULTS: Out of 713 studies identified, seven studies met the selection criteria for the meta-analysis. At 6 and 12 months of denosumab therapy, increases in BMD were observed in the lumbar spine (2.99% [95% CI 2.71, 3.28] and 4.59% [95% CI 4.17, 5.01]), total hip (1.34% [95% CI 0.64, 2.04] and 2.16% [95% CI 2.05, 2.27]) and femoral neck (0.12% [95% CI −0.38, 0.62] and 1.55% [95% CI 0.45, 2.65]). Additionally, denosumab resulted in significant increases in BMD in the lumbar spine and femoral neck at 12 months compared with bisphosphonate therapy. CONCLUSION: Patients with GIO experienced significant increases in BMD in response to treatment with denosumab that were detected in the lumbar spine, total hip and femoral neck at 12 months.
format Online
Article
Text
id pubmed-7197806
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-71978062020-05-05 The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis Yamaguchi, Yuta Morita, Takayoshi Kumanogoh, Atsushi Rheumatol Adv Pract Meta-Analysis OBJECTIVE: Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients with GIO. METHODS: A comprehensive systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PubMed, Web of Science and Google Scholar were used to search for original studies reported about BMD in patients with GIO treated with denosumab. In meta-analysis of BMD, the mean difference in the rate of change from baseline and the 95% CI were calculated using the random effects model. The mean differences in patients treated with denosumab were compared with those in patients treated with bisphosphonates. RESULTS: Out of 713 studies identified, seven studies met the selection criteria for the meta-analysis. At 6 and 12 months of denosumab therapy, increases in BMD were observed in the lumbar spine (2.99% [95% CI 2.71, 3.28] and 4.59% [95% CI 4.17, 5.01]), total hip (1.34% [95% CI 0.64, 2.04] and 2.16% [95% CI 2.05, 2.27]) and femoral neck (0.12% [95% CI −0.38, 0.62] and 1.55% [95% CI 0.45, 2.65]). Additionally, denosumab resulted in significant increases in BMD in the lumbar spine and femoral neck at 12 months compared with bisphosphonate therapy. CONCLUSION: Patients with GIO experienced significant increases in BMD in response to treatment with denosumab that were detected in the lumbar spine, total hip and femoral neck at 12 months. Oxford University Press 2020-03-13 /pmc/articles/PMC7197806/ /pubmed/32373775 http://dx.doi.org/10.1093/rap/rkaa008 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meta-Analysis
Yamaguchi, Yuta
Morita, Takayoshi
Kumanogoh, Atsushi
The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title_full The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title_fullStr The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title_full_unstemmed The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title_short The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
title_sort therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197806/
https://www.ncbi.nlm.nih.gov/pubmed/32373775
http://dx.doi.org/10.1093/rap/rkaa008
work_keys_str_mv AT yamaguchiyuta thetherapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis
AT moritatakayoshi thetherapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis
AT kumanogohatsushi thetherapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis
AT yamaguchiyuta therapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis
AT moritatakayoshi therapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis
AT kumanogohatsushi therapeuticefficacyofdenosumabforthelossofbonemineraldensityinglucocorticoidinducedosteoporosisametaanalysis